



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

12th November, 2014

The Manager - Listing
Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001.

National Stock Exchange of India Ltd
"Exchange Plaza,
Bandra – Kurla Complex
Bandra (E),
Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

We wish to inform you that the Board of Directors at their meeting held on today taken on record the following:

1. Unaudited Financial Results (Standalone and Consolidated) and Report of Segment wise Revenue, Results and Capital employed for the Quarter ended 30th September, 2014 as per Clause 41 of the Listing Agreement along with Limited Review Report by the Statutory Auditors. Please find enclosed a copy of the same.
2. Mr.P.S.R.K.Prasad, Executive Vice President (Corporate Engineering Services) appointed as Additional Director of the Company who will be in the wholetime employment of the Company.
3. Mr.S.V.V.N.Appa Rao, Vice President (Finance & Accounts) appointed as Interim (Chief Financial Officer) of the Company.

Thanking you,

Yours faithfully,
for NATCO Pharma Limited

M Adinarayana
Company Secretary &
V.P. (Legal & Corporate Affairs)
Encl: as above.



Statement of stand-alone Financial Results for the quarter ended 30th September, 2014

Rs. lakhs

PART I : STATEMENT OF STAND-ALONE RESULTS						
PARTICULARS	THREE MONTHS ENDED (REVIEWED)			YEAR-TO-DATE FIGURES FOR THE HALF YEAR ENDED (REVIEWED)		YEAR ENDED (AUDITED)
	30-SEP-2014	30-JUN-2014	30-SEP-2013	30-SEP-2014	30-SEP-2013	31-MAR-2014
01. Gross Sales / Income from Operations	18677	16950	13778	35627	27856	58960
Less : Excise Duty	215	342	134	557	249	582
Less : Sales Tax	351	408	269	759	547	1174
Net Sales / Income from Operations	18111	16200	13375	34311	27060	57204
02. Other Operating Income	1017	1948	1631	2965	2428	5029
03. TOTAL INCOME FROM OPERATIONS	19128	18148	15006	37276	29488	62233
04. EXPENDITURE						
a) Cost of materials consumed	3820	3892	3755	7712	7626	16670
b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	725	477	-227	1202	-502	-1597
c) Employee benefits expense	2909	2715	2214	5624	4419	9422
d) Depreciation and amortization expense	1023	1019	656	2042	1297	2679
e) Other Expenses	5586	5008	4601	10594	8773	19080
TOTAL EXPENSES	14063	13111	10999	27174	21613	46254
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	5065	5037	4007	10102	7875	15979
06. Other Income	300	88	177	388	527	1571
07. Profit / (Loss) from ordinary activities before finance costs and exceptional items	5365	5125	4184	10490	8402	17550
08. Finance costs	699	636	957	1335	1915	3405
09. Profit / (Loss) from ordinary activities after finance costs but before exceptional items	4666	4489	3227	9155	6487	14145
10. Exceptional Items	-	-	-	-	-	-
11. Profit / (Loss) from ordinary activities before tax	4666	4489	3227	9155	6487	14145
12. Tax expense, including deferred tax	1186	848	358	2034	1344	3126
13. Net Profit / Loss (-) from ordinary activities after tax	3480	3641	2869	7121	5143	11019
14. Extraordinary items (net of tax expense)	-	-	-	-	-	-
15. Net Profit / (Loss) for the period	3480	3641	2869	7121	5143	11019
16. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3307	3307	3137	3307	3137	3307
17. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						69983
18. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.) - non-annualized	10.52 10.52	11.01 11.01	9.15 9.15	21.53 21.53	16.40 16.40	34.49 34.49
PART II : SELECT INFORMATION						
19. Public Shareholding:						
a) Number of Shares	15,373,943	15,373,943	13,611,493	15,373,943	13,611,493	15,365,107
b) Percentage of Shareholding	46.48	46.48	43.39	46.58	43.39	46.46
20. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered -						
b) Non - encumbered - No. of shares	17,699,131	17,699,131	17,761,581	17,699,131	17,761,581	17,707,9671
Percentage (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100
Percentage (as a % of the total share capital of the company)	53.52	53.52	56.61	53.52	56.61	53.54

Dated at Hyderabad, this, the 12th day of November, 2014
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Naganapaneni
Chairman & Managing Director

Status of Investor Complaints as at 30th September, 2014

Pending as on 01-07-2014	Nil
Received during the quarter	87
Resolved during the quarter	87
Pending as on 30-09-2014	Nil



Report of segment wise revenue, Results and Capital Employed, under Clause 41 of the Listing Agreement, for the quarter ended on 30th September, 2014

Rs. lakhs

	THREE MONTHS ENDED (Reviewed)			HALF YEAR ENDED (Reviewed)		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-SEP-2014	30-JUN-2014	30-SEP-2013	30-SEP-2014	30-SEP-2013	31-MAR-2014
01. Segment Revenue (Net)						
a) Bulk Chemicals	7431	8527	5570	15958	11940	22101
b) Formulations	11882	8966	9616	20848	16104	38702
c) Job Work	206	230	418	436	613	1193
d) Unallocated	240	970	38	1210	1879	2386
Total	19759	18693	15642	38452	30536	64382
Less : Inter-segment Revenue	631	545	636	1176	1048	2149
Net Sales / Income from Operations	19128	18148	15006	37276	29488	62233
02. Segment Results : Profit (+)/Loss (-) before tax and interest						
a) Bulk Chemicals	761	3957	1051	4718	2568	4581
b) Formulations	6579	3068	4474	9647	6660	16857
c) Job Work	178	183	332	361	471	984
d) Unallocated	41	53	21	94	1694	2109
Total	7559	7261	5878	14820	11393	24531
Less : a) Interest	699	636	957	1335	1915	3405
b) Other unallocable expenditure	2494	2224	1871	4718	3518	8552
c) Unallocable income	(300)	(88)	(177)	(388)	(527)	(1571)
Total Profit Before Tax	4666	4489	3227	9155	6487	14145
03. Capital Employed (Segment Assets - Segment Liabilities)						
a) Bulk Chemicals	46920	45748	37017	46920	37017	39578
b) Formulations	40074	30176	35170	40074	35170	38238
c) Job Work	173	212	295	173	295	165
e) Unallocated (Others)	-7170	173	-13468	-7170	-13468	-4691
Total	79997	76309	59014	79997	59014	73290

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 12th November, 2014. In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful lives and residual value of the fixed assets and (i) An amount of ₹411 lakhs (net of deferred tax charge of ₹ 212 lakhs) has been charged to the opening balance of the retained earnings in respect of assets whose remaining useful life is nil as at 1 April 2014, ii) The profit for the quarters ended 30 September 2014, 30 June 2014 and period ended 30 September 2014 has decreased by ₹299 lakhs, ₹306 lakhs and ₹605 lakhs respectively on account of application of Schedule II.

In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

Dated at Hyderabad, this, the 12th day of November, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Statement of Stand-alone Assets & Liabilities (Rs. Lakhs)		
	As at	
	30 September 2014	31 March 2014
	Reviewed	Audited
I. Equity and liabilities		
<i>Shareholders' funds</i>		
Share capital	3,307	3,307
Reserves and surplus	76,690	69,983
	79,997	73,290
<i>Non-current liabilities</i>		
Long-term borrowings	7,713	9,497
Deferred tax liabilities (net)	4,123	4,233
Other long-term liabilities	77	69
Long-term provisions	1,134	1,063
	13,047	14,862
<i>Current liabilities</i>		
Short-term borrowings	14,389	9,863
Trade payables	8,429	9,918
Other current liabilities	11,603	9,648
Short-term provisions	41	41
	34,462	29,470
Total	127,506	1,17,622
II. Assets		
<i>Non-current assets</i>		
Fixed assets		
Tangible assets	51,700	52,319
Intangible assets	522	579
Capital work-in-progress	10,689	9,294
Non-current investments	9,751	8,858
Long-term loans and advances	14,325	12,516
Other non-current assets	260	322
	87,247	83,888
<i>Current assets</i>		
Current investments	5	32
Inventories	15,854	16,197
Trade receivables	18,919	11,584
Cash and bank balances	834	770
Short-term loans and advances	4,377	4,899
Other current assets	270	252
	40,259	33,734
	127,506	1,17,622

Statement of consolidated Financial Results for the quarter ended 30th September, 2014

Rs. lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS						
PARTICULARS (REFER NOTES BELOW)	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR-TO-DATE FIGURES (UNREVIEWED/UNAUDITED) FOR THE HALF YEAR ENDED ON		YEAR ENDED (AUDITED)
	30-SEP-2014	30-JUN-2014	30-SEP-2013	30-SEP-2014	30-SEP-2013	31-MAR-2014
01. Gross Sales / Income from Operations	21532	19809	16712	41341	33597	70656
Less : Excise Duty	267	366	150	633	296	630
Less : Sales Tax	359	413	271	772	556	1182
Net Sales / Income from Operations	20906	19030	16291	39936	32745	68844
02. Other Operating Income	1017	1948	1631	2965	2428	5045
03. TOTAL INCOME FROM OPERATIONS	21923	20978	17922	42901	35173	73889
04. EXPENDITURE						
a) Cost of materials consumed	5716	6062	6013	11779	11758	16010
b) Purchases of stock-in-trade	-	-	-	-	-	8889
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	725	477	-227	1202	-502	-1577
d) Employee benefits expense	3369	3157	2633	6526	5222	11277
e) Depreciation and amortization expense	1115	1114	747	2229	1478	3045
f) Other Expenses	6230	5531	5155	11761	9879	21356
TOTAL EXPENSES	17153	16341	14321	33494	27835	59000
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	4770	4637	3601	9407	7338	14889
06. Other Income	319	118	198	437	548	1671
07. Finance costs	724	656	1002	1380	1998	3662
08. Exceptional item	-	-	-	-	-	-
09. Profit / (Loss) from ordinary activities before tax	4365	4099	2797	8464	5888	12898
10. Tax expense, including deferred tax	1241	878	371	2119	1385	3087
11. Minority Interest	-113	-125	-266	-238	-367	-463
12. Net Profit / Loss (-) from ordinary activities after tax	3237	3346	2692	6583	4870	10274
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3307	3307	3137	3307	3137	3307
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						69280
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	9.79	10.12	8.58	19.91	15.52	32.16
	9.79	10.12	8.58	19.91	15.52	32.16
PART II : SELECT INFORMATION						
16. Public Shareholding:						
a) Number of Shares	15,373,943	15,373,943	13,611,493	15,373,943	13,611,493	15,365,107
b) Percentage of Shareholding	46.48	46.48	43.39	46.48	43.3	46.46
16. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered – No. of shares	-	-	-	-	-	-
b) Non – encumbered – No. of shares	17,699,131	17,699,131	17,761,581	17,699,131	17,761,581	1,77,07,967
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100	100.00
Percentage (as a % of the total share capital of the company)	53.52	53.52	56.61	53.52	56.61	53.54

The above un-audited financial results were reviewed by the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 12th November, 2014. In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful lives and residual value of the fixed assets and (i) An amount of ₹411 lakhs (net of deferred tax charge of ₹ 212 lakhs) has been charged to the opening balance of the retained earnings in respect of assets whose remaining useful life is nil as at 1 April 2014, ii) The profit for the quarters ended 30 September 2014, 30 June 2014 and period ended 30 September 2014 has decreased by ₹299 lakhs, ₹306 lakhs and ₹605 lakhs respectively on account of application of Schedule II

Dated at Hyderabad, this, the 12th November, 2014.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V. G. Nannapaneni

Chairman & Managing Director

Status of Investor Complaints as at 30th September, 2014

Pending as on 01-07-2014	Nil
Received during the quarter	87
Resolved during the quarter	87
Pending as on 30-09-2014	Nil

Statement of Consolidated Assets & Liabilities (Rs. Lakhs)		
	As at	
	30 September 2014	31 March 2014 (Audited)
I. Equity and liabilities		
<i>Shareholders' funds</i>		
a) Share capital	3307	3307
b) Reserves and surplus	75948	69280
	79255	72587
c) Minority interest	1205	688
<i>Non-current liabilities</i>		
a) Long-term borrowings	7713	9549
b) Deferred tax liabilities (net)	4198	4305
c) Other long term liabilities	126	105
d) Long-term provisions	1180	1109
	13217	15068
<i>Current liabilities</i>		
a) Short-term borrowings	14595	9863
b) Trade payables	9824	10979
c) Other current liabilities	12121	10218
d) Short-term provisions	93	168
Sub-total	36633	31228
Total	130310	119571
II. Assets		
<i>Non-current assets</i>		
a) Fixed assets		
Tangible assets	60653	61274
Intangible assets	5039	3200
b) Capital work-in-progress	13934	12377
c) Non-current investments	157	157
d) Long-term loans and advances	5524	5425
e) Other non-current assets	378	324
	85685	82757
<i>Current assets</i>		
a) Current investments	5	32
b) Inventories	17780	18113
c) Trade receivables	20118	11880
d) Cash and bank balances	998	1105
e) Short-term loans and advances	4687	5432
f) Other current assets	1037	252
	44625	36814
Total	130310	119571